ABSTRACT
A new Monoclonal Antibody (AcMo) ior-C5, highly specific for the most part of colorectal adenocarcinomas has been developed. The AcMo was labeled with 99mTc by the Schwarz's direct method using molar ratios MAb: reductant of 1:1,000 and 1:2,000. The first molar ratio was the most adequate for the preparation of the radiopharmaceutical. A labeling yield greater than 95% was obtained. Several <